Masitinib in treatment of pancreatic cancer
- 26 March 2018
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 19 (7) , 759-764
Abstract
Introduction: Pancreatic cancer continues to have high mortality despite the development of many chemotherapeutic agents. The 5-year relative survival for stage IV patients is less than 3%. This urgent unmet need warrants the development of novel and active therapeutic agents, which focus both on targeting cancer cells and modifying the microenvironment of cancer cells. Areas covered: In this article, the authors review the development of masitinib, a novel tyrosine kinase inhibitor of numerous targets, including c-Kit, PDGFR and FGFR. This review covers its development from the bench to clinical trials assessing its potential in pancreatic cancer. Expert opinion: While masitinib has not shown an increase in overall survival (OS) or progression free survival (PFS) compared to the current standard of care in patients with pancreatic adenocarcinoma, masitinib may have a role in decreasing inflammation related to those patients with increased pain scores with pancreatic adenocarcinoma. If we have the tools to identify accurate subgroups of patients who may benefit from particular therapies, this agent may be of benefit to these patients. Indeed, if more sophisticated biomarkers and the identification of patient subgroups are better explained, the authors believe that masitinib will become part of the armamentarium against pancreatic adenocarcinoma.Keywords
This publication has 22 references indexed in Scilit:
- Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal AdenocarcinomaClinical Cancer Research, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205Journal of Clinical Oncology, 2010
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)Journal of Clinical Oncology, 2010
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2009
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KITPLOS ONE, 2009
- Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancersEuropean Journal of Cancer, 2009
- Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the PancreasThe Cancer Journal, 2009
- Masitinib is Safe and Effective for the Treatment of Canine Mast Cell TumorsJournal of Veterinary Internal Medicine, 2008
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerBMC Cancer, 2008